Mirus to Study Gene Silencing for Pfizer | GenomeWeb
NEW YORK (GenomeWeb News) — Mirus Bio yesterday said it has signed a two-year, “multi-million dollar” deal with Pfizer to target and suppress the expression of certain genes.
 
Under the deal, Mirus said it will study methods for optimizing gene silencing methods in animals.
 
Mirus said the agreement will help it speed development of delivery methods for its RNAi technology.
 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The final text of the bill to reauthorize the America COMPETES Act might smooth over the differences between NSF and the House science committee, ScienceInsider says.

Four Republican lawmakers urge President-elect Donald Trump to keep Francis Collins as NIH director, Stat News reports.

In Genome Research this week: Platinum variant catalog, algorithmic strategy for upgrading fragmented assemblies, and more.

Sequencing of a 10,000-year-old mummy leads to its repatriation to the Fallon Paiute-Shoshone Tribe, Nature News reports.